DUBLIN–(BUSINESS WIRE)–The “Allergic Rhinitis (Respiratory) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Allergic Rhinitis – Drugs In Development, 2021, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.
Report Highlights
Allergic Rhinitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 1, 11, 12, 16, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 4 molecules, respectively.
Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Allergic Rhinitis – Overview
- Allergic Rhinitis – Therapeutics Development
- Allergic Rhinitis – Therapeutics Assessment
- Allergic Rhinitis – Companies Involved in Therapeutics Development
- Allergic Rhinitis – Drug Profiles
- Allergic Rhinitis – Dormant Projects
- Allergic Rhinitis – Discontinued Products
- Allergic Rhinitis – Product Development Milestones
- Appendix
Companies Mentioned
- Advagene Biopharma Co Ltd
- ALK-Abello AS
- Allovate LLC
- AOBiome LLC
- ASIT Biotech SA
- Astellas Pharma Inc
- Bai Shuo Beijing Pharmaceutical Technology Co Ltd
- Cadila Healthcare Ltd
- Chrysalis BioTherapeutics Inc
- CSPC Pharmaceutical Group Ltd
- Dobecure SL
- DongKoo Bio & Pharma Co Ltd
- Emergo Therapeutics Inc
- FunPep Co Ltd
- GL Pharm Tech Corp
- Glenmark Pharmaceuticals Ltd
- HAL Allergy BV
- Inimmune Corp
- Inmunotek SL
- Kolmar Pharma Co Ltd
- Liminal BioSciences Inc
- Link Health Group
- Marinomed Biotech AG
- MD Healthcare Inc
- Mitsubishi Tanabe Pharma Corp
- Nasus Pharma Ltd
- Navipharm Co Ltd
- Novartis AG
- Oneness Biotech Co Ltd
- Paradigm Biopharmaceuticals Ltd
- PharmaKing Co Ltd
- Regeneron Pharmaceuticals Inc
- Roxall Medizin GmbH
- Sama Pharm Co Ltd
- Sedor Pharmaceuticals LLC
- Shouyao Holding Co Ltd
- Siolta Therapeutics Inc
- Stallergenes Greer Ltd
- Synokem Pharmaceuticals Ltd
- The Geneva Biotech Center SA
- United Biomedical Inc
- Vactech Oy
- Wolwo Pharma
- Wuhan Yicheng Biotechnology Co Ltd
For more information about this report visit https://www.researchandmarkets.com/r/9ihta9
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900